Read our COVID-19 research and news.

Webinar Technology

Detecting Disease in Blood: What miRNA Biomarkers Can Tell Us

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Detecting Disease in Blood: What miRNA Biomarkers Can Tell Us

Recorded 30 May 2012



microRNAs (miRNAs) are becoming increasingly recognized as powerful biomarkers for human disease. The information potential held by miRNAs, combined with the fact that they are stable in serum and plasma, has led to a rapidly growing interest in using miRNAs in blood as diagnostic and prognostic biomarkers. This webinar will present the latest advances that are allowing researchers to move miRNA biomarker research from discovery in the lab to application in the clinic.

During the webinar, our expert panel of researchers will discuss:
• Strategies and technologies for successful cancer biomarker discovery through robust detection and analysis of miRNAs in biofluids
• Research into analytic and biological variables that impact miRNA measurements in serum and plasma from the clinical pathologist’s point of view
• The novel application of miRNAs in serum as biomarkers of aging and chronic disease
• The answers to questions submitted by the live, online viewers.

For related product information, go to:

Speaker bios

Colin C. Pritchard M.D., Ph.D.

University of Washington
Seattle, WA

Dr. Pritchard completed his undergraduate and graduate training at the University of Washington in Seattle in the United States. He completed his medical training at the University of Washington School of Medicine. Dr. Pritchard is an assistant professor of Laboratory Medicine as well as the associate director of the Clinical Molecular Genetics Laboratory at the University of Washington Medical Center. His research focuses predominantly on oncology molecular diagnostics, particularly the source and utility of miRNA biomarkers in blood, and the development of innovative molecular diagnostics for the identification of mutations that can guide therapeutic decision-making. In 2009, Dr. Pritchard was the winner of the Young Investigator Award from the Academy of Clinical Laboratory Physicians and Scientists.

Monty Montano, Ph.D.

Boston University School of Medicine
Boston, MA

Dr. Montano received his B.A. in biochemistry from the University of California, Berkeley, his Ph.D. in genetics from Stanford University, and conducted his postdoctoral work at the Harvard School of Public Health in Cambridge, Massachusetts. He is currently a principal investigator at the Boston Medical Center in the Department of Medicine, in the sections of Infectious Diseases and Molecular Medicine. Dr. Montano’s laboratory is broadly interested in the identification of biomarkers for immune/muscle interaction in infection, muscle wasting, fibrosis, and aging. Research initiatives in his laboratory include analysis of the interaction between host immune factors (e.g., macrophages) and muscle stem cell remodeling during HIV-associated muscle wasting, and the molecular phenotyping of aging and identification of biomarkers for anabolic response. Dr. Montano is also a principal investigator on a Boston OAIC Pepper Center project to identify biomarkers for anabolic response.

Adam Baker, Ph.D.

Vedbaek, Denmark

Dr. Baker holds a Ph.D. in Molecular biology and Genetics from The Research Institute of Molecular Pathology in Vienna, Austria. Following his graduate work, he undertook his postdoctoral training at Boehringer Ingelheim, subsequently obtaining a senior scientist position at Chromos Molecular Systems in Vancouver, Canada. Before joining Exiqon, Dr. Baker headed the Division for New Technologies at deCODE genetics in Iceland for seven years. Today he holds the position of director of Communication, Biomarkers and Clinical Sciences at Exiqon. He works closely with clinical research groups and Exiqon's pharmaceutical partners to develop microRNA based diagnostics solutions based on LNA™ technology.

Sean Sanders, Ph.D.

Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently, Dr. Sanders is the Director and Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here